GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Cyclically Adjusted PB Ratio

AVANIR Pharmaceuticals (FRA:AV2B) Cyclically Adjusted PB Ratio : (As of May. 17, 2024)


View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVANIR Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AVANIR Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Cyclically Adjusted PB Ratio Chart

AVANIR Pharmaceuticals Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVANIR Pharmaceuticals Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVANIR Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVANIR Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



AVANIR Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AVANIR Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2014 is calculated as:

For example, AVANIR Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Sep. 2014 was:

Adj_Book=Book Value per Share/CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=1.095/100.4278*100.4278
=1.095

Current CPI (Sep. 2014) = 100.4278.

AVANIR Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
200412 0.318 80.290 0.398
200503 0.048 81.555 0.059
200506 0.318 82.062 0.389
200509 0.275 83.876 0.329
200512 1.206 83.032 1.459
200603 0.948 84.298 1.129
200606 0.483 85.606 0.567
200609 -0.142 85.606 -0.167
200612 -0.069 85.142 -0.081
200703 -0.113 86.640 -0.131
200706 -0.105 87.906 -0.120
200709 0.097 87.964 0.111
200712 0.031 88.616 0.035
200803 -0.043 90.090 -0.048
200806 0.306 92.320 0.333
200809 0.258 92.307 0.281
200812 0.229 88.697 0.259
200903 0.193 89.744 0.216
200906 0.139 91.003 0.153
200909 0.170 91.120 0.187
200912 0.132 91.111 0.145
201003 0.089 91.821 0.097
201006 0.288 91.962 0.315
201009 0.226 92.162 0.246
201012 0.768 92.474 0.834
201103 0.567 94.283 0.604
201106 0.478 95.235 0.504
201109 0.417 95.727 0.437
201112 0.380 95.213 0.401
201203 0.331 96.783 0.343
201206 0.276 96.819 0.286
201209 0.210 97.633 0.216
201212 0.145 96.871 0.150
201303 0.171 98.209 0.175
201306 0.116 98.518 0.118
201309 0.091 98.790 0.093
201312 0.043 98.326 0.044
201403 0.125 99.695 0.126
201406 0.286 100.560 0.286
201409 1.095 100.428 1.095

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVANIR Pharmaceuticals  (FRA:AV2B) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AVANIR Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Traded in Other Exchanges
N/A
Address
Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines